![Amy Quinlan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Amy Quinlan
Comptroller/Controller/Auditor bei
VOYAGER THERAPEUTICS, INC.
Vermögen: 126 784 $ am 31.08.2026
Profil
Amy Quinlan is Chief Accounting Officer at Voyager Therapeutics, Inc. since 2026, with employment at the firm starting in 2025.
Formerly, Ms. Quinlan was Vice President-Finance at Vor Biopharma, Inc. from 2024 to 2025 and Vice President & Controller at Tetraphase Pharmaceuticals, Inc. from 2008 to 2020.
Education includes an undergraduate degree from Bryant University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 08.05.2026 | 36’749 ( 0.06% ) | 126 784 $ | 31.08.2026 |
Aktive Positionen von Amy Quinlan
| Unternehmen | Position | Beginn |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 08.05.2025 |
Ehemalige bekannte Positionen von Amy Quinlan
| Unternehmen | Position | Ende |
|---|---|---|
| VOR BIOPHARMA INC. | Comptroller/Controller/Auditor | 30.09.2024 |
| TETRAPHASE PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01.08.2020 |
Ausbildung von Amy Quinlan
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
55
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
Bryant University
 Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Voyager Therapeutics, Inc.
 Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
Vor Biopharma, Inc.
 Vor Biopharma, Inc. BiotechnologyHealth Technology Engages in developing cell therapies | Health Technology |
